


E KW 6002/CN

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN  
RN 155270-99-8 REGISTRY  
ED Entered STN: 24 May 1994  
CN 1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-  
3,7-dihydro-7-methyl- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 1H-Purine-2,6-dione, 8-[2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-  
dihydro-7-methyl-, (E)-  
OTHER NAMES:  
CN Istradefylline  
CN KW 6002  
FS STEREOSEARCH  
MF C20 H24 N4 O4  
CI COM  
SR CA  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA,  
CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, EMBASE, IMSPATENTS, IMSRESEARCH,  
IPA, MEDLINE, MRCK\*, PROMT, PROUSDDR, RTECS\*, SYNTHLINE, TOXCENTER,  
USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Double bond geometry as shown.



SET EXPAND CONTINUOUS  
L1 1 S E3  
FILE 'HCAPLUS' ENTERED AT 14:21:41 ON 20 APR 2010  
L2 113 S L1  
L3 3 S L2 AND (COGNITION OR COGNITIVE)  
L4 0 S L3 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)  
FILE 'HCAPLUS' ENTERED AT 14:22:38 ON 20 APR 2010  
L5 1 S US 20070078148/PN  
L6 2 S L1 AND MEMORY, BIOLOGICAL/IT  
L7 54 S L2 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)  
L8 1 S L6 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)  
L8 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Xanthine derivatives and salts and compositions for preventing  
 and/or  
 treating higher brain dysfunction  
 AB A preventive and/or therapeutic agent for higher brain  
 dysfunctions which contains as an active ingredient a xanthine  
 derivative represented, for example, by the following formula (I)  
 or a pharmacol. acceptable salt thereof: (I) (II) wherein R1, R2,  
 and R3 are the same or different and each represents hydrogen,  
 lower alkyl, lower alkenyl, or lower alkynyl; R4 represents  
 cycloalkyl, -(CH2)n-R5, or the formula (II) given above; and X1  
 and X2 are the same or different and each represents oxygen or  
 sulfur. The higher brain dysfunction includes aging brain damage,  
 brain trauma, cerebrovascular disease, memory disorder, thinking  
 disorder, recognition disorder, behavior disorder, learning  
 disorder, etc.

ACCESSION NUMBER: 2005:547543 HCAPLUS Full-text  
 DOCUMENT NUMBER: 143:53542  
 TITLE: Xanthine derivatives and salts and  
 compositions for  
 preventing and/or treating higher brain  
 dysfunction  
 INVENTOR(S): Kase, Hiroshi; Nakagawa, Yutaka; Shiozaki,  
 Shizuo;  
 Kobayashi, Minoru; Toki, Shinichiro; Seno,  
 Naoki;  
 Ikeda, Ken  
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056016	A1	20050623	WO 2004-JP18765	
20041209 <--				
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,			
CA, CH,	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,			
GB, GD,	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,			
KZ, LC,	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,			
NA, NI,	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,			
SL, SY,	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,			
ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,			
ZW, AM,	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,			
DE, DK,	EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL,			
PL, PT,				

RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML,

MR, NE, SN, TD, TG  
AU 2004296137 A1 20050623 AU 2004-296137  
20041209 <--  
CA 2550130 A1 20050623 CA 2004-2550130  
20041209 <--  
EP 1709966 A1 20061011 EP 2004-807124  
20041209 <--  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,  
MC, PT,

IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS  
CN 1889959 A 20070103 CN 2004-80036267  
20041209 <--  
BR 2004017241 A 20070306 BR 2004-17241  
20041209 <--  
US 20070078148 A1 20070405 US 2006-579829  
20060517 <--  
MX 2006005965 A 20060809 MX 2006-5965  
20060525 <--  
KR 2006124615 A 20061205 KR 2006-711123  
20060607 <--  
ZA 2006004723 A 20091125 ZA 2006-4723  
20060608 <--  
IN 2006CN02490 A 20070608 IN 2006-CN2490  
20060706 <--  
PRIORITY APPLN. INFO.: JP 2003-410432 A  
20031209 <--  
WO 2004-JP18765 W

20041209

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): MARPAT 143:53542

IC ICM A61K031-522  
ICS A61P025-28; C07D473-12; C07D473-06

CC 1-11 (Pharmacology)  
Section cross-reference(s): 63

IT Behavior  
Memory, biological  
(recognition; xanthine derivs. and salts and compns. for  
preventing  
and/or treating higher brain dysfunction)

IT 51-34-3, Scopolamine 69-89-6D, Xanthine, derivs. and salts  
51389-37-8

141807-96-7 155270-99-8 155272-00-7  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(xanthine derivs. and salts and compns. for preventing and/or  
treating  
higher brain dysfunction)

L9 3 S L1 AND MEMORY  
L10 1 S L9 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)  
L11 0 S L10 NOT L8  
L12 1 S L1 AND LEARNING DISORDERS/IT  
L13 0 S L12 NOT L8  
L14 5 S L1 AND BRAIN, DISEASE/IT  
L15 3 S L14 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)

L16 2 S L15 NOT L8  
 L17 5 S L1 AND TRAUMA?  
 L18 2 S L17 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)  
 L19 1 S L18 NOT L8

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2010 ACS on STN  
 TI A method using an adenosine A2A receptor antagonist for treating  
 an

anxiety disorder

AB Anxiety disorders, such as panic disorder, agoraphobia, obsessive-  
 compulsive disorder, social phobia, post-traumatic stress  
 disorder, generalized anxiety disorder, specific phobia, or the  
 like, are treated by administering an effective amount of at least  
 one adenosine A2A receptor antagonist (e.g. a xanthine derivative)  
 to a patient in need thereof, optionally in combination with an  
 anxiolytic(s) other than the adenosine A2A receptor antagonist.

ACCESSION NUMBER: 2004:1080800 HCAPLUS Full-text

DOCUMENT NUMBER: 142:33005

TITLE: A method using an adenosine A2A receptor  
 antagonist

INVENTOR(S): for treating an anxiety disorder  
 Kase, Hiroshi; Seno, Naoki; Shiozaki, Shizuo;  
 Kobayashi, Minoru; Kase, Junya

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108137	A1	20041216	WO 2004-JP8486	
20040610 <--				
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,			
CA, CH,	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,			
GB, GD,	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,			
KZ, LC,	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,			
NA, NI,	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,			
SL, SY,	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,			
ZM, ZW	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,			
ZW, AM,	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,			
DE, DK,	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT,			
RO, SE,	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,			
MR, NE,	SN, TD, TG			

AU 2004244906	A1	20041216	AU 2004-244906
20040610 <--			
CA 2528710	A1	20041216	CA 2004-2528710
20040610 <--			
EP 1631294	A1	20060308	EP 2004-746014
20040610 <--			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1787821	A	20060614	CN 2004-80012845
20040610 <--			
BR 2004011120	A	20060718	BR 2004-11120
20040610 <--			
JP 2006527264	T	20061130	JP 2006-516839
20040610 <--			
US 20060281770	A1	20061214	US 2005-553250
20051017 <--			
KR 2006037252	A	20060503	KR 2005-721878
20051116 <--			
MX 2005013148	A	20060317	MX 2005-13148
20051205 <--			
NO 2005005907	A	20051213	NO 2005-5907
20051213 <--			
IN 2006CN00077	A	20070629	IN 2006-CN77
20060106 <--			
PRIORITY APPLN. INFO.:			US 2003-509046P P
20030610 <--			US 2003-532793P P
20031224 <--			WO 2004-JP8486 W

20040610

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OTHER SOURCE(S): MARPAT 142:33005

IC ICM A61K031-522  
ICS A61K031-519; A61P025-22  
CC 1-11 (Pharmacology)  
IT Mental and behavioral disorders  
(post-traumatic stress disorder; adenosine A2A receptor antagonist for treating anxiety disorders)  
IT 69-89-6D, Xanthine, derivs. 51389-37-8 99331-25-6D, Triazolopyrimidine, derivs. 155270-99-8 262452-04-0 377727-87-2  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(adenosine A2A receptor antagonist for treating anxiety disorders)

L20	7 S L1 AND IMPAIR?
L21	2 S L20 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L22	2 S L21 NOT L8
L23	2 S L22 NOT L19